Global Respiratory Drugs Pipeline Analysis Market 2018

  • Product Code:
    RP-ID-10078106
  • Published Date:
    Mar 2019
  • Region:
    Global
  • Pages:
    188
  • Category:
    Healthcare & Pharmaceuticals
  • Publisher:
    Infoholic Research
Respiratory Drugs Pipeline Analysis
Overview: Pulmonary medicine is the branch of medical science that deals with diagnosis, prevention, and treatment of diseases affecting the respiratory system. Respiratory drugs finds its applications in Asthma, COPD, Cystic Fibrosis, Allergic Rhinitis and Others. Asthma is the major market share holder currently. The intensity of competition in the respiratory drug market is high with few players dominating the market. The high investments made in the development of respiratory drug delivery systems have favored the growth of the market. The entry of innovative and effective drugs in the market is expected to drive the future of the market.
Short-Acting Beta2-Agonists (SABA), Inhaled corticosteroids (ICS), anticholinergics, long-acting beta2-agonists (LABA), antihistamines, vasodilators, combination drugs, and others are the major respiratory dugs classes available in the market. Currently, primarily combination drugs drive the market, with top brands facing no real competition from generic alternatives. The emergence of inexpensive, state-of-the-art and effective drug delivery devices will provide stimulate the market growth.
Industry Trends
• GSK’s Adavir for Asthma and COPD remains as the top selling drug in the market, even on declined revenue in 2017
• Pharmaceutical companies in US are facing pricing pressure and launch of new respiratory drugs in the market are declining the sales of the blockbuster drugs in the market
• Cipla Ltd., a leader in the Indian market, announced in May 2017, that it planned to reduce the investment on the biosimilars, to increase their focus on the respiratory drugs due to the high profitability
More than 30 companies pipeline for the respiratory drugs is analyzed in the study. GlaxoSmithKline plc has the highest number of pipeline molecules in various clinical trials phases.
Benefits: The report provides complete details about the usage and adoption rate of respiratory drugs in various regions. With that, key stakeholders can know about the major trends, drivers, investments, and vertical player’s initiatives. Moreover, the report provides details about the major challenges that are going to impact on the market growth. Additionally, the report gives the complete details about the key business opportunities to key stakeholders to expand their business and capture the revenue in the specific verticals to analyze before investing or expanding the business in this market.
Key Stakeholders:


Table of Contents
1 Industry Outlook 12
1.1 Industry Overview 12
1.1.1 Global Driver for Pharmaceutical Demand: 13
1.1.2 Pharmaceutical spending region wise 13
1.1.3 R&D pipeline in pharmaceutical industry 13
1.1.4 Top pharma drugs by sales in 2017 ($Million) 15
1.2 Industry Trends 17
1.3 Pest Analysis 17
2 Report Outline 19
2.1 Report Scope 19
2.2 Report Summary 19
2.3 Research Methodology 19
2.4 Report Assumptions 20
3 Market Snapshot 21
3.1 Market Definition – Infoholic Research 21
3.2 Segment Addressable Market 21
3.1 Trends of Respiratory Drugs Market 21
4 Molecule Type: Analysis 23
4.1 Overview 23
5 Application: Analysis 25
5.1 Overview 25
5.2 Asthma 25
5.2.1 Key Takeaways 30
5.2.2 Company Analysis 31
5.3 Chronic Obstructive Pulmonary Disease (COPD) 31
5.3.1 Key Takeaways 35
5.3.2 Company Analysis 36
5.4 Cystic Fibrosis 36
5.4.1 Key Takeaways 40
5.4.2 Company Analysis 40
5.5 Lung Cancer 40
5.5.1 Key Takeaways 45
5.5.2 Company Analysis 46
5.6 Nasal Polyps 46
5.6.1 Key Takeaways 47
5.7 Idiopathic Pulmonary Fibrosis 48
5.7.1 Key Takeaways 50
5.7.2 Company Analysis 50
5.8 Others 51
6 Competitive Landscape 52
6.1.1 Company Analysis 53
7 Vendors Profile 55
7.1 AbbVie Inc. 55
7.1.1 Overview 55
7.1.2 Geographic Presence 58
7.1.3 Business Focus 58
7.1.4 SWOT Analysis 59
7.1.5 Business Strategies 59
7.2 Amgen Inc. 60
7.2.1 Overview 60
7.2.2 Geographic Presence 63
7.2.3 Business Focus 64
7.2.4 SWOT Analysis 65
7.2.5 Business Strategies 67
7.3 Astra Zeneca PLC 67
7.3.1 Overview 67
7.3.2 Geographic Presence 71
7.3.3 Business Focus 71
7.3.4 SWOT Analysis 72
7.3.5 Business Strategy 72
7.4 Bayer AG 73
7.4.1 Overview 73
7.4.2 Business Unit 74
7.4.3 Geographic Presence 75
7.4.4 Business Focus 76
7.4.5 SWOT Analysis 76
7.4.6 Business Strategy 77
7.5 Boehringer Ingelheim GmbH 77
7.5.1 Overview 77
7.5.2 Geographic Presence 81
7.5.3 Business Focus 81
7.5.4 SWOT Analysis 81
7.5.5 Business Strategy 82
7.6 Bristol-Myers Squibb 83
7.6.1 Overview 83
7.6.2 Geographic Presence 87
7.6.3 Business Focus 87
7.6.4 SWOT Analysis 87
7.6.5 Business Strategy 88
7.7 Celgene Corporation 89
7.7.1 Overview 89
7.7.2 Geographic Presence 90
7.7.3 Business Focus 91
7.7.4 SWOT Analysis 91
7.7.5 Business Strategy 92
7.8 Dr. Reddy’s Laboratories Limited 93
7.8.1 Overview 93
7.8.2 Business Unit 97
7.8.3 Geographic Presence 99
7.8.4 Business Focus 99
7.8.5 SWOT Analysis 100
7.8.6 Business Strategy 100
7.9 Eli Lilly & Company Ltd 101
7.9.1 Overview 101
7.9.2 Business Focus 103
7.9.3 SWOT Analysis 104
7.9.4 Business Strategies 104
7.10 F.Hoffmann-La Roche Ltd. 105
7.10.1 Overview 105
7.10.2 Business Unit 108
7.10.3 Geographic Presence 109
7.10.4 Business Focus 109
7.10.5 SWOT Analysis 110
7.10.6 Business Strategy 110
7.11 GlaxoSmithKline plc 111
7.11.1 Overview 111
7.11.2 Geographic Presence 115
7.11.3 Business Focus 115
7.11.4 SWOT Analysis 116
7.11.5 Business Strategy 116
7.12 Johnson & Johnson 117
7.12.1 Overview 117
7.12.2 Business Units 120
7.12.3 Geographic Revenue 121
7.12.4 Business Focus 122
7.12.5 SWOT Analysis 123
7.12.6 Business Strategies 123
7.13 Merck & Co., Inc. 124
7.13.1 Overview 124
7.13.2 Business units 126
7.13.3 Geographic Revenue 127
7.13.4 Business focus 128
7.13.5 SWOT analysis 128
7.13.6 Business strategies 129
7.14 Mylan N.V. 129
7.14.1 Overview 129
7.14.2 Geographic Presence 133
7.14.3 Business Focus 133
7.14.4 SWOT Analysis 134
7.14.5 Business Strategy 134
7.15 Novartis AG 134
7.15.1 Overview 134
7.15.2 Business Unit 136
7.15.3 Geographic Presence 137
7.15.4 Business Focus 138
7.15.5 SWOT Analysis 138
7.15.6 Business Strategy 139
7.16 Pfizer, Inc., 140
7.16.1 Overview 140
7.16.2 Business Units 143
7.16.3 Geographic Presence 143
7.16.4 Business Focus 144
7.16.5 SWOT Analysis 144
7.16.6 Business Strategies 144
7.17 Sanofi 145
7.17.1 Overview 145
7.17.2 Geographic Presence 148
7.17.3 Business Focus 148
7.17.4 SWOT Analysis 148
7.17.5 Business Strategy 149
7.18 Teva Pharmaceutical Industries Ltd. 149
7.18.1 Overview 149
7.18.2 Business Unit 152
7.18.3 Geographic Presence 152
7.18.4 Business focus 153
7.18.5 SWOT analysis 153
7.18.6 Business Strategy 154
7.19 Vertex Pharmaceuticals Inc. 155
7.19.1 Overview 155
7.19.2 Geographic Presence 158
7.19.3 Business Focus 158
7.19.4 SWOT Analysis 159
7.19.5 Business Strategy 159
8 Companies to Watch For 160
8.1 FibroGen, Inc 160
8.1.1 Overview 160
8.1.2 Highlights 160
8.2 Gilead Sciences Inc. 161
8.2.1 Overview 161
8.2.2 Highlights: 162
8.3 Glenmark Pharmaceutical Ltd 163
8.3.1 Overview 163
8.4 Zia Labs 164
8.4.1 Overview 164
8.4.2 Zia Lab: Highlights 164
8.5 Vectura Group Plc 165
8.5.1 Overview 165
8.5.2 Vectura Group Plc: Highlights 166
8.6 Sosei Group Corporation 166
8.6.1 Overview 166
8.7 Almirall S.A. 167
8.7.1 Overview 167
8.8 Biogen Inc 168
8.8.1 Overview 168
8.9 CHIESI Farmaceutici SpA 169
8.9.1 Overview 169
8.9.2 CHIESI Farmaceutici SpA: Highlights 170
8.10 Takeda Pharmaceutical Co, Ltd 170
8.10.1 Overview 170
8.10.2 Highlights 171
8.11 Shionogi & Co., Ltd 171
8.11.1 Overview 171
8.11.2 Shionogi & Co., Ltd: Highlights 172
8.12 Sun Pharmaceuticals 172
8.12.1 Overview 172
8.12.2 Highlights 173
8.13 United Therapeutics Corp 173
8.13.1 Overview 173
8.13.2 Highlights 174
8.14 ProMetic Life Sciences Inc. 174
8.14.1 Overview 174
8.14.2 ProMetic Life Sciences Inc.: Highlights 175
8.15 Daiichi Sankyo, Inc. 175
8.15.1 Overview 175
8.15.2 Overview 176
8.16 Aurobindo Pharma Ltd 176
8.16.1 Overview 176
8.16.2 Aurobindo Pharma Ltd: Highlights 177
8.17 Eisai Co., Ltd 177
8.17.1 Overview 177
8.17.2 Eisai Co., Ltd: Highlights 178
8.18 Shire Plc 179
8.18.1 Overview 179
8.18.2 Shire Plc: Highlights 181
8.19 GNI Group Ltd 181
8.19.1 Overview 181
8.20 MediciNova, Inc 182
8.20.1 Overview 182
8.21 Ono Pharmaceutical Co., Ltd 182
8.21.1 Overview 182
8.22 Promedior, Inc 183
8.22.1 Overview 183
8.23 Sumitomo Dainippon Pharma Co., Ltd. 184
8.23.1 Overview 184
8.23.2 Sumitomo Dainippon Pharma Co., Ltd: Highlights 185
9 Annexure 186
Abbreviations 186

Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report
AbbVie Inc.Amgen Inc.Astra Zeneca PLCBayer Dr. Reddy’s Laboratories Limited Eli Lilly & Company LtdF.Hoffmann-La Roche Ltd.GlaxoSmithKline plcMerck & Co., Inc.Mylan N.V. AG,Boehringer Ingelheim GmbH
Please enter your personal details below
*
I want to buy this report
I am willing to know the scope of research
I have customized query over this report

Related Reports